Liver Cancer Treatment in India
Expert liver cancer treatment in India — hepatic resection, TACE, radiofrequency ablation, liver transplant, and sorafenib therapy. Costs 70% lower than Western countries.
Estimated cost: $4,000 – $12,000 · Average stay: 7–14 days
Liver cancer — most commonly hepatocellular carcinoma (HCC) — is the sixth most common cancer worldwide and the third leading cause of cancer mortality, with approximately 900,000 new cases diagnosed globally each year. The majority of HCC cases develop in livers already damaged by chronic hepatitis B or C infection, heavy alcohol use, or metabolic fatty liver disease — making its prevention, surveillance, and early detection critically important.
Treatment options have expanded significantly over the past decade. For early-stage disease, surgical resection and liver transplantation offer the best chance of cure, with 5-year survival rates reaching 60–70%. Patients unsuitable for surgery benefit from locoregional therapies — radiofrequency ablation (RFA) for small tumors, and transarterial chemoembolization (TACE) for larger, multifocal disease — which control tumor growth and bridge patients to transplant or surgery.
India has established itself as one of the world's leading destinations for liver cancer treatment. Hospitals such as Medanta, Global Hospitals, and Apollo perform some of the highest volumes of liver resections and transplants in Asia, with outcomes comparable to leading Western centers. Medical costs in India are 70–80% lower than equivalent care in the US or UK.
Gaf Healthcare coordinates comprehensive liver cancer care for international patients in India, from initial molecular diagnosis through surgery, locoregional therapy, systemic treatment, and transplant listing where appropriate.
Types of Liver Cancer and Staging
Hepatocellular carcinoma (HCC) accounts for 75–85% of primary liver cancers. The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used classification:
BCLC Stage 0 (Very early): Single tumor ≤2 cm, excellent liver function. Surgical resection achieves 5-year survival >70%. BCLC Stage A (Early): Single tumor or up to 3 nodules ≤3 cm, preserved liver function. Resection or transplant is curative. BCLC Stage B (Intermediate): Multiple tumors confined to the liver, good liver function. TACE is the standard treatment. BCLC Stage C (Advanced): Vascular invasion or extrahepatic spread. Systemic therapy (sorafenib, lenvatinib, atezolizumab + bevacizumab) is used. BCLC Stage D (Terminal): Severe liver dysfunction. Best supportive care is recommended.
Intrahepatic cholangiocarcinoma and gallbladder cancer are other primary liver tumors treated at specialized hepatobiliary centers. Liver metastases from colorectal, breast, and other primary cancers are also managed with surgical and locoregional techniques.
Who Qualifies for Liver Cancer Treatment?
Patient selection for each treatment modality is guided by tumor stage, number and size of lesions, degree of liver function preservation, and performance status.
Surgical resection candidates: patients with single or limited HCC nodules, no major vascular invasion, and preserved liver function (Child-Pugh A). A minimum future liver remnant of 25–40% (depending on liver health) is required. Preoperative portal vein embolization can increase the remnant and expand surgical candidacy.
Liver transplant candidates: patients meeting Milan criteria (single tumor ≤5 cm, or up to 3 nodules each ≤3 cm, no vascular invasion, no extrahepatic spread) achieve excellent post-transplant outcomes, with 5-year survival of 70%. Living donor transplant from a healthy family member is more accessible than deceased donor organ waiting in India.
TACE candidates: patients with intermediate-stage (BCLC B) multifocal HCC confined to the liver with preserved liver function who are not surgical candidates. TACE doubles median overall survival compared to best supportive care.
RFA candidates: patients with early-stage HCC (≤3 cm) who are not surgical candidates due to comorbidity or liver function impairment.
Liver Cancer Treatment: Surgery, Ablation, and Systemic Therapy
Liver cancer treatment is highly individualized and coordinated by dedicated hepatobiliary multidisciplinary teams including hepatic surgeons, interventional radiologists, transplant hepatologists, and medical oncologists.
Hepatic resection removes the tumor-bearing liver segment (segmentectomy or lobectomy) with adequate margins. Anatomic resection — removing the complete Couinaud segment — offers lower recurrence rates than non-anatomic wedge excision. Laparoscopic hepatectomy is performed at high-volume centers with equivalent oncologic results and faster recovery.
Transarterial chemoembolization (TACE): a microcatheter is threaded through the femoral artery to the hepatic artery feeding the tumor, where chemotherapy (doxorubicin, cisplatin) is infused and the artery occluded with embolic particles. This delivers concentrated chemotherapy to the tumor while cutting off its blood supply.
Radiofrequency ablation (RFA): a thin electrode is inserted percutaneously into the tumor under ultrasound or CT guidance and heated to destroy cancer cells. Ideal for tumors ≤3 cm in size.
Systemic therapy: atezolizumab + bevacizumab is the preferred first-line regimen for advanced HCC, improving overall survival compared to sorafenib. Lenvatinib and sorafenib are used as alternatives.
Procedure Steps
- Comprehensive evaluation: AFP tumor marker, liver function tests, CT/MRI liver with contrast, and hepatitis B/C serology.
- Liver biopsy if diagnosis uncertain; HCC can often be diagnosed radiologically by characteristic arterial enhancement and washout pattern.
- BCLC staging and multidisciplinary tumor board review to determine optimal treatment strategy.
- For resection: preoperative portal vein embolization if needed to grow the future remnant; laparoscopic or open hepatectomy.
- For transplant: Milan criteria confirmation; living donor evaluation; TACE as bridge therapy during waiting period.
- For TACE: interventional radiology procedure under conscious sedation; may be repeated every 4–8 weeks.
- For RFA: percutaneous ablation under ultrasound/CT guidance; outpatient procedure for small tumors.
- Systemic therapy (advanced disease): atezolizumab + bevacizumab; sorafenib or lenvatinib as alternatives.
Liver Cancer Treatment Options
Hepatic Resection (Surgery)
Surgical removal of the liver segment containing the tumor with adequate margins. Offers the best chance of cure for resectable early-stage HCC. Laparoscopic approach reduces hospital stay and recovery time. Five-year survival exceeds 60% in well-selected patients.
Cost: $5,000 – $12,000
Liver Transplant
Replacement of the entire diseased liver with a healthy donor organ for patients meeting Milan criteria. Addresses both the cancer and the underlying liver disease. Living donor transplant is more accessible in India, with excellent outcomes at high-volume transplant centers.
Cost: $30,000 – $45,000
TACE (Transarterial Chemoembolization)
Locoregional therapy delivering concentrated chemotherapy directly to the tumor via the hepatic artery while blocking the tumor's blood supply. Standard treatment for intermediate-stage multifocal HCC. Can be repeated and used as a bridge to transplant.
Cost: $2,500 – $5,000 per session
Radiofrequency Ablation (RFA)
Percutaneous thermal ablation for small (≤3 cm) HCC tumors using a CT or ultrasound-guided electrode. An outpatient procedure with minimal recovery time. Achieves complete ablation in over 90% of tumors under 3 cm.
Cost: $2,000 – $4,000
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $4,000 – $12,000 — Save 70–80%
UAE — $8,000 – $18,000 — Save 55–65%
USA / UK — $30,000 – $100,000+ — Baseline
Liver cancer treatment in India costs 70–80% less than equivalent care in the United States, yet is delivered by surgeons and hepatologists who have trained at leading international institutions and work in JCI-accredited facilities. Sorafenib and lenvatinib are available as affordable generics in India. Living donor liver transplants, which circumvent long waiting lists, are accessible and legal under strict protocols.
Recovery & Follow-up
Recovery after liver resection depends on the extent of surgery. Minor resection (segmentectomy) allows discharge in 5–7 days; major hepatectomy may require 8–12 days. Liver function typically normalizes within 4–8 weeks as the remaining liver regenerates. After TACE, most patients experience 3–7 days of post-embolization syndrome (fever, pain, nausea) before returning to normal activity. After RFA, recovery is typically 1–3 days.
Recovery Tips
- Abstain completely from alcohol after liver cancer surgery or locoregional therapy — alcohol accelerates liver damage and promotes recurrence.
- Follow the prescribed diet: high-protein, low-fat meals in small frequent portions during the recovery period.
- If you have chronic hepatitis B, antiviral medication (entecavir or tenofovir) must be continued indefinitely after treatment.
- AFP tumor marker should be measured every 1–3 months after treatment; a rising AFP signals recurrence before it is clinically apparent.
- Keep all follow-up imaging appointments — CT or MRI every 3–4 months for the first 2 years after treatment.
Risks & Complications
Liver resection risks include post-hepatectomy liver failure (risk depends on remnant volume), bile leak, bleeding, and infection. Post-embolization syndrome after TACE (fever, pain, nausea) is expected and temporary. RFA risks include bleeding, bile duct injury, and incomplete ablation for tumors near major vessels. Systemic therapy risks include hypertension and hand-foot syndrome (sorafenib/lenvatinib) and immune-related events (atezolizumab). All risks are discussed in pre-treatment informed consent.
Why GAF Healthcare
Gaf Healthcare works with India's highest-volume hepatobiliary and transplant centers. Our partner hospitals perform over 300 liver transplants annually — among the highest volumes in Asia. We coordinate complete evaluations, tumor board case presentations, and all logistics for international patients traveling for liver cancer treatment, including living donor evaluation coordination.
Frequently Asked Questions
What is the survival rate for liver cancer in India?
Survival depends on stage and treatment. After hepatic resection: 5-year survival of 50–65%. After liver transplant meeting Milan criteria: 5-year survival of 65–75%. After TACE for intermediate disease: median survival of 26–30 months. After systemic therapy for advanced disease: median overall survival of 19–22 months with atezolizumab + bevacizumab.
Can I get a liver transplant in India as an international patient?
Yes. India permits living donor liver transplant for international patients under strict legal guidelines. A first-degree relative or spouse can donate a portion of their liver. Deceased donor transplants are generally not accessible to international patients due to national organ allocation priorities.
What is TACE and how many sessions will I need?
TACE (transarterial chemoembolization) delivers chemotherapy directly into the tumor's blood supply. Most patients require 2–4 sessions every 4–8 weeks, guided by tumor response on follow-up CT imaging. TACE is well tolerated as a day-case or overnight procedure.
Is sorafenib available in India?
Yes. Sorafenib (Nexavar) and lenvatinib (Lenvima) are available at Indian cancer centers. Generic sorafenib is available at significantly lower cost than branded versions in Western countries, making advanced HCC treatment far more affordable.
How do I know if my liver cancer is resectable?
Resectability is determined by the size and location of the tumor, the quality and volume of remaining liver, and absence of major vascular invasion or distant metastasis. A dedicated hepatobiliary surgeon's review of your CT/MRI images is the most important step — Gaf Healthcare can arrange this within 48–72 hours of receiving your scans.